🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Vimta Labs Limited VIMTALABS NSEPHARMA

Healthcare · Diagnostics & Research · India
https://vimta.com
Company Profile ↓
₹588.65
+29.40% 1Y
Mkt Cap₹2,629.46 Cr
P/E33.83
P/B5.44
Div. Yield0.35%
52W High₹873.97
52W Low₹379.30
Book Value₹102.28
EPS (TTM)₹17.40

Company Overview

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It provides solutions to agriculture, biologics and biosimilars, home and personal care, medical device, specialty chemicals, food, electrical and electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, environment, health and safety, and packaging industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.0%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 21.0%.

Consistent Profit Growth

Net profit has compounded at 17.2% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 33.8, below the sector median of 40.0.

Healthy Margins

Maintains a net profit margin of 19.0%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹407.29 Cr (+18.4% YoY); net profit ₹77.51 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +18.4%, earnings +15.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.9%, profit CAGR 17.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.94%
1 Year:18.40%

Compounded Profit Growth

5 Years:17.18%
1 Year:15.10%

Stock Price Performance

1 Year:+29.40%
6 Months:+2.30%
3 Months:+24.70%
1 Month:+8.21%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 42% of range
₹379.30 ₹873.97
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.08 · Neutral
Price Performance
1M+8.21%
3M+24.70%
6M+2.30%
1Y+29.40%
Valuation vs Sector

P/E of 33.83 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 21.0%.
  • Profit CAGR of 17.2% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 32.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
33.83
Industry PE
39.97
Forward P/E est.
29.39
PEG Ratio
-
Book Value
₹102.28
Price to Book
5.44
P/S
6.07
EV/EBITDA
16.81
Dividend Yield
0.35%

Growth (CAGR)

Revenue 5Y
8.94%
Profit 5Y
17.18%
Revenue (YoY)
18.40%
Earnings (YoY)
15.10%

Profitability & Returns

ROCE
21.03%
ROE
16.97%
ROA
13.79%
Profit Margin
19.03%
Op Margin
26.20%
Gross Margin
80.16%
EPS (Latest Qtr)
₹4.62
EPS (TTM)
₹17.40

Balance Sheet & Liquidity

Debt/Equity
0.73
Quick Ratio
2.97
Current Ratio
3.43
Debt
₹3.33 Cr
Total Assets
₹562.23 Cr
Current Assets
₹224.87 Cr
Working Capital
₹159.35 Cr

Ownership

Promoter Holding
65.87%
Chg in Prom Hold
-0.03%
FII / Inst Holding
4.11%
Chg in FII Hold
-0.06%

Financial Snapshot

Enterprise Value
₹2,629.46 Cr
Total Revenue (TTM)
₹407.29 Cr
EBITDA
₹148.24 Cr
Free Cash Flow
₹47.34 Cr
Operating Cash Flow
₹147.14 Cr
Shares Outstanding
₹4.47 Cr
Gross Margin
80.16%
Payout Ratio
5.75%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VIMTALABS Vimta Labs Limited NSEPHARMA 588.65 33.83 ₹2,629.46 Cr 0.35% 21.03% 16.97% 8.94% 17.18%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 67.00 Cr74.00 Cr79.00 Cr80.00 Cr77.00 Cr82.00 Cr83.00 Cr66.00 Cr75.00 Cr80.00 Cr75.00 Cr85.00 Cr90.00 Cr94.44 Cr97.56 Cr101.85 Cr98.63 Cr109.25 Cr
Cost of Revenue -------------18.18 Cr18.81 Cr20.15 Cr19.36 Cr22.48 Cr
Gross Profit -------------76.26 Cr78.75 Cr81.70 Cr79.27 Cr86.77 Cr
Operating Expenses 47.00 Cr51.00 Cr55.00 Cr54.00 Cr56.00 Cr58.00 Cr59.00 Cr48.00 Cr51.00 Cr55.00 Cr49.00 Cr55.00 Cr57.00 Cr52.44 Cr54.93 Cr57.71 Cr55.96 Cr60.15 Cr
Operating Income 15.00 Cr16.00 Cr17.00 Cr17.00 Cr13.00 Cr16.00 Cr17.00 Cr8.00 Cr16.00 Cr16.00 Cr18.00 Cr22.00 Cr23.00 Cr23.82 Cr23.83 Cr23.99 Cr23.31 Cr26.62 Cr
EBITDA 21.00 Cr23.00 Cr24.00 Cr25.00 Cr21.00 Cr24.00 Cr25.00 Cr17.00 Cr24.00 Cr24.00 Cr26.00 Cr30.00 Cr33.00 Cr34.68 Cr35.44 Cr36.89 Cr34.45 Cr42.12 Cr
Interest Expense 01.00 Cr1.00 Cr1.00 Cr1.00 Cr001.00 Cr1.00 Cr1.00 Cr001.00 Cr43.80 L31.50 L37.40 L15.70 L32.10 L
Pretax Income 15.00 Cr16.00 Cr17.00 Cr18.00 Cr14.00 Cr17.00 Cr16.00 Cr8.00 Cr14.00 Cr16.00 Cr17.00 Cr20.00 Cr28.00 Cr25.03 Cr25.26 Cr26.27 Cr23.37 Cr29.05 Cr
Tax Provision 3.75 Cr4.32 Cr4.76 Cr4.68 Cr3.78 Cr3.91 Cr4.00 Cr2.00 Cr3.50 Cr3.84 Cr4.42 Cr4.80 Cr6.44 Cr6.71 Cr6.37 Cr6.35 Cr5.79 Cr7.93 Cr
Net Income 12.00 Cr12.00 Cr12.00 Cr13.00 Cr10.00 Cr13.00 Cr12.00 Cr6.00 Cr10.00 Cr12.00 Cr12.00 Cr15.00 Cr22.00 Cr18.32 Cr18.89 Cr19.92 Cr17.59 Cr21.11 Cr
Diluted EPS 2.642.682.722.992.322.862.751.432.292.792.773.444.844.044.214.443.944.62

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 181.00 Cr211.00 Cr278.00 Cr315.06 Cr288.60 Cr343.98 Cr407.29 Cr
Cost of Revenue ---73.85 Cr57.66 Cr71.45 Cr80.79 Cr
Gross Profit ---241.21 Cr230.94 Cr272.54 Cr326.50 Cr
Operating Expenses 151.00 Cr158.00 Cr198.00 Cr171.53 Cr166.48 Cr181.93 Cr219.80 Cr
Operating Income 9.00 Cr30.00 Cr57.00 Cr69.68 Cr64.46 Cr90.60 Cr106.70 Cr
EBITDA 30.00 Cr53.00 Cr80.00 Cr96.64 Cr98.22 Cr126.12 Cr148.24 Cr
Interest Expense 4.00 Cr2.00 Cr2.00 Cr92.80 L1.52 Cr1.39 Cr51.10 L
Pretax Income 8.00 Cr29.00 Cr56.00 Cr65.00 Cr62.50 Cr89.00 Cr103.95 Cr
Tax Provision 1.36 Cr7.25 Cr14.56 Cr16.82 Cr13.69 Cr22.25 Cr26.44 Cr
Net Income 7.00 Cr21.00 Cr41.00 Cr48.17 Cr41.01 Cr67.34 Cr77.51 Cr
Diluted EPS 1.554.849.3510.689.1214.9317.40

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024Mar 2025Mar 2026
Total Assets 246.00 Cr274.00 Cr-362.32 Cr394.47 Cr440.00 Cr466.53 Cr562.23 Cr
Current Assets ---163.66 Cr157.60 Cr-187.82 Cr224.87 Cr
Cash & Equivalents ---30.50 Cr13.44 Cr-15.84 Cr22.97 Cr
Inventory ---22.62 Cr24.69 Cr-25.06 Cr29.95 Cr
Receivables ---79.99 Cr87.00 Cr-106.24 Cr105.70 Cr
Total Liabilities ---80.54 Cr80.35 Cr-87.68 Cr105.36 Cr
Current Liabilities ---57.28 Cr54.07 Cr-64.37 Cr65.52 Cr
Long Term Debt ---9.89 Cr9.07 Cr-3.22 Cr1.56 Cr
Total Debt 33.00 Cr30.00 Cr-14.99 Cr19.19 Cr12.00 Cr8.52 Cr3.33 Cr
Total Equity 172.00 Cr194.00 Cr-281.79 Cr314.12 Cr342.00 Cr378.85 Cr456.87 Cr
Shares Outstanding ---4.43 Cr4.43 Cr-4.45 Cr4.47 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 24.00 Cr37.00 Cr-87.94 Cr60.89 Cr94.05 Cr147.14 Cr
Investing Cash Flow -21.00 Cr-32.00 Cr--57.26 Cr-76.05 Cr-75.54 Cr-129.67 Cr
Financing Cash Flow -1.00 Cr-5.00 Cr--10.98 Cr-1.90 Cr-16.12 Cr-10.35 Cr
Capital Expenditure -15.00 Cr-33.00 Cr--49.80 Cr-76.57 Cr-79.49 Cr-99.80 Cr
Free Cash Flow 9.00 Cr4.00 Cr-38.13 Cr-15.68 Cr14.56 Cr47.34 Cr
Net Change in Cash 3.00 Cr1.00 Cr-19.70 Cr-17.06 Cr2.40 Cr7.12 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---76.6%80.0%79.2%80.2%
Operating Margin % 5.0%14.2%20.5%22.1%22.3%26.3%26.2%
Net Margin % 3.9%10.0%14.7%15.3%14.2%19.6%19.0%
ROE % 4.1%10.8%-17.1%13.1%17.8%17.0%
ROCE % ---22.8%18.9%22.5%21.5%

Shareholding Pattern

Insiders
65.87%
Institutions
4.11%
Public Float
12.05%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VIMTALABS

Google News Sun, 14 Jun 2026

Vimta Labs Limited (NSE:VIMTALABS) Looks Interesting, And It's About To Pay A Dividend - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNN1NSRjA3ME1pX2s1ZzVnOE5QYnF1V21hbDZ1Z1hzZHdpMnNPUVNVU3o5V0I2LTFKOVhkMG1lRXdHQzBEVjc4M0E2djNQYklxdjRfN1lwNnl6TDgwTjk0OWIxRU9hRnJOTlVlMmc0R3Z3NHZmZm9NdWZRN2R6ZmM1Mjd3RG1NMFZiX2lsLU…

Google News Wed, 17 Jun 2026

Tata Tech, Vimta Labs, Capital Small Finance Bank, GHCL Dividend Record Date: Last Day To Buy Shares To Qualify - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxQRTVibGExRHNCSnRQWDVMMkJIRE9MUzlnQkdkU2xoQlczUkNJMl9ZaDFwZU1tc2hjRUV0MU9zWDd2NVR2dGw5MUVGUmRaVlIxNy1TTjZvdEJhZEMwQlZRRlkwRlhXX3hXbHUzU3hqeUUzdURRWjV5SjMtSkhOQndWd2dfMzBzeHNKSVdOOW…

Google News Fri, 30 Jan 2026

Vimta Labs Limited (NSE:VIMTALABS) May Have Run Too Fast Too Soon With Recent 29% Price Plummet - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNdFJ4Yzk4YlZqOEdkeEdBVEEwV1FwQmVITHFSY1ZkTWtjZ1BIcVVmMHpUa1J4X1dObGw1VzhhSlFoWVN2Q294ZEtwQy1zTmNxcG9CVlpRbmNhT2xJRzltcE9kenhUcnlOX3p4UjM4b0FBdGpVNXlEemtXenE2dmU3WERjUVp1RGl3dm5rQ0…

Google News Wed, 06 May 2026

Vimta Labs FY26 Revenue Rises 19.5%; Dividend Declared - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNU01vdXp6UjlGQnB3M0huejRsRk4xTlpBUGxkMEoybWF2NkdRRFNzeENvY0xsYkhBNlg4VWwyczNqSkhTQWhkMnJsZ19pSkppZ0FFY3hSTVFZMzhJRHp2eWRPREZXVnFjY2dvdzAtaDBXR3BXNm5Ha1NpQktBS05iQzRaWFhaeXR4QjRVaT…

Google News Mon, 03 Nov 2025

Vimta Labs Q2 Revenue Hits ₹104.5 Cr, Up 22.3% YoY - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQaWVMcXg1M3VuR0tiWm1tWkdubVRybnAwdmZqOE9rOXhfcXBJWnJTS2dzX3dpOHJYdi13MHdUUmlGR0daREIwVmdfTlItaXJidlZmM1RzdEpVeVFIeU9QaDVSeWszUEJTUFotWEk4Sk5rM0d4cmtSck5oME1xVHJLUkplTGdyMHlSQllDQQ…

Google News Sat, 03 Jan 2026

Vimta Labs Ltd. Share Price Today - Vimta Labs Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE9GT3A3VHVmeEdWNTFUeW8tSWZ3OWNWU2xjQ3NOam5KWE8xVi0wYURLZXJoM1NtOVRJYjJQMVdON2l3Ym56bHItS1NUczlkbUg1dXFqakdKNXViWXU1NURZRkRVZTVyMEdJVXJsektRal9wNVZfbGJXd2cxMA?oc=5" target="_blank">V…

VIMTALABS — Frequently Asked Questions

What is the current share price of Vimta Labs Limited (VIMTALABS)?

As of 2026-07-15 09:52 IST, Vimta Labs Limited (VIMTALABS) trades at ₹588.65 on NSE. Its 52-week range is ₹379.30 to ₹873.97.

What is the market capitalisation of VIMTALABS?

Vimta Labs Limited (VIMTALABS) has a market capitalisation of ₹2,629.46 Cr on NSE.

What is the P/E ratio of VIMTALABS?

VIMTALABS trades at a trailing price-to-earnings (P/E) ratio of 33.83. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.44.

Does VIMTALABS pay a dividend?

Vimta Labs Limited (VIMTALABS) currently offers a dividend yield of 0.35%.

What is the return on equity (ROE) of VIMTALABS?

VIMTALABS has a return on equity (ROE) of 16.97%. Its return on capital employed (ROCE) is 21.03%.

Is VIMTALABS a good stock to buy?

This page provides a data-driven analysis of Vimta Labs Limited (VIMTALABS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space